GFAP and proximal spinal muscular atrophy: Taken together, while GFAP concentrations in CSF show some association with disease severity in SMA, particularly in younger patients with more severe forms (e.g., type 1), they do not serve as a reliable diagnostic or prognostic biomarker, especially in adults or milder SMA subtypes (type 2/3) [48,51].